We are live on
!
Find out more
Ensign Peak Advisors Portfolio holdings
AUM
$53.7B
1-Year Est. Return
29.47%
This Fund
S&P 500
This Quarter
Est. Return
+4.27%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
–
AUM
$56.6B
AUM Growth
-$4.33B
(-7.1%)
Cap. Flow
-$5.51B
Cap. Flow
% of AUM
-9.73%
Top 10 Holdings %
Top 10 Hldgs %
36.93%
Holding
1,739
New
42
Increased
177
Reduced
1,384
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$201M |
| 2 |
Oracle
ORCL
|
+$135M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$123M |
| 4 |
Invesco MSCI USA ETF
PBUS
|
+$80.7M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$267M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$183M |
| 3 |
NVIDIA
NVDA
|
+$172M |
| 4 |
JPMorgan Chase
JPM
|
+$137M |
| 5 |
Apple
AAPL
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.12% |
| 2 | Financials | 12.63% |
| 3 | Healthcare | 12.38% |
| 4 | Communication Services | 10.27% |
| 5 | Consumer Discretionary | 9.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Natera
NTRA
$36B
| $35.1M | 0.06% |
153,326
-46,398
| -23% | -$9.68M |
|
227
Air Products & Chemicals
APD
$66.3B
| $34.9M | 0.06% |
141,486
-55,649
| -28% | -$14.1M |
|
|
MRSH
228
Marsh
MRSH
$90.2B
| $34.9M | 0.06% |
188,090
+49,784
| +36% | +$9.31M |
|
229
Waters Corp
WAT
$37.8B
| $34.8M | 0.06% |
91,740
-16,342
| -15% | -$6.01M |
|
230
IDEAYA Biosciences
IDYA
$3.47B
| $33.8M | 0.06% |
979,063
+225,899
| +30% | +$7.2M |
|
231
Freeport-McMoran
FCX
$87.3B
| $33.7M | 0.06% |
663,796
-307,806
| -32% | -$13.3M |
|
232
Idexx Laboratories
IDXX
$45.4B
| $33.6M | 0.06% |
49,695
+4,365
| +10% | +$2.97M |
|
233
Syndax Pharmaceuticals
SNDX
$1.76B
| $33.6M | 0.06% |
1,598,544
+789,480
| +98% | +$13.8M |
|
234
Synopsys
SNPS
$74.1B
| $33.6M | 0.06% |
71,451
+5,082
| +8% | +$2.26M |
|
235
Cardinal Health
CAH
$54.3B
| $32.8M | 0.06% |
159,558
-96,528
| -38% | -$18.2M |
|
236
Howmet Aerospace
HWM
$114B
| $32.6M | 0.06% |
158,993
-5,108
| -3% | -$1.02M |
|
237
Newmont
NEM
$96.7B
| $32.3M | 0.06% |
323,708
+50,301
| +18% | +$4.54M |
|
238
Equitable Holdings
EQH
$13.3B
| $31M | 0.05% |
651,388
-360,633
| -36% | -$17.1M |
|
239
Eaton
ETN
$146B
| $31M | 0.05% |
97,307
-7,997
| -8% | -$2.83M |
|
240
Travere Therapeutics
TVTX
$5.19B
| $30.8M | 0.05% |
805,215
-46,987
| -6% | -$1.53M |
|
241
Royalty Pharma
RPRX
$26.3B
| $30.5M | 0.05% |
790,302
-16,550
| -2% | -$631K |
|
|
FISV
242
Fiserv Inc
FISV
$28.5B
| $30.5M | 0.05% |
453,491
-29,153
| -6% | -$2.44M |
|
243
Doximity
DOCS
$3.78B
| $30.3M | 0.05% |
684,621
-55,809
| -8% | -$3.13M |
|
244
MetLife
MET
$62.3B
| $30.2M | 0.05% |
383,202
-133,156
| -26% | -$10.5M |
|
245
Madrigal Pharmaceuticals
MDGL
$12.6B
| $29.7M | 0.05% |
51,010
-2,257
| -4% | -$1.15M |
|
246
Hartford Financial Services
HIG
$39.3B
| $29.7M | 0.05% |
215,423
-49,966
| -19% | -$6.59M |
|
247
Equinix
EQIX
$103B
| $29.5M | 0.05% |
38,518
-24,767
| -39% | -$19.4M |
|
|
WCC
248
WESCO International
WCC
$16.1B
| $29.3M | 0.05% |
119,800
-31,855
| -21% | -$7.81M |
|
249
iShares MSCI ACWI ex US ETF
ACWX
$11.2B
| $29.3M | 0.05% |
436,044
+64,513
| +17% | +$4.27M |
|
250
Fortive
FTV
$19.6B
| $29.2M | 0.05% |
528,339
-101,082
| -16% | -$5.25M |
|
Similar funds
SCP
Ensign Peak Advisors's Q4 2025 Portfolio in Review
As of Q4 2025, Ensign Peak Advisors held 1,739 positions worth $56.6B, down 7.1% from $60.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Ensign Peak Advisors withdrew a net $5.51B in Q4 2025, closing 54 positions and reducing 1,384 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $125M position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 33% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Ensign Peak Advisors opened a new position in Invesco MSCI USA ETF worth $81.3M.
- Ensign Peak Advisors's largest Q4 2025 buy was Invesco MSCI USA ETF: 1,188,232 shares worth $81.3M.
- Ensign Peak Advisors added most to Eli Lilly in Q4 2025, an estimated $201M increase.
- Ensign Peak Advisors's biggest Q4 2025 reduction was Meta Platforms (Facebook), cutting an estimated $267M.
- Ensign Peak Advisors fully exited iShares Core S&P 500 ETF in Q4 2025, selling an estimated $125M.
- Ensign Peak Advisors's ten largest holdings make up 37% of its $56.6B portfolio in Q4 2025.
- Ensign Peak Advisors opened 42 new positions and closed 54 in Q4 2025.
- Ensign Peak Advisors's portfolio value fell 7.1% quarter-over-quarter to $56.6B.
Based on Ensign Peak Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.